Categories Earnings Calls, Health Care

Moderna, Inc. (MRNA) Q1 2021 Earnings Call

Moderna, Inc. (NASDAQ: MRNA) Q1 2021 earnings call dated May. 06, 2021

Corporate Participants:

Lavina Talukdar — Senior Vice President and Head of Investor Relations

Stephane Bancel — Chief Executive Officer

Corinne Le Goff — Chief Commercial Officer

David Meline — Chief Financial Officer

Stephen Hoge — President


Salveen Richter — Goldman Sachs — Analyst

Matthew Harrison — Morgan Stanley — Analyst

Edward Tenthoff — Piper Sandler — Analyst

Michael Yee — Jefferies — Analyst

Gena Wang — Barclays — Analyst

Geoffrey Meacham — Bank of America — Analyst

Cory Kasimov — J.P. Morgan — Analyst

Hartaj Singh — Oppenheimer & Co. — Analyst

Joseph Stringer — Needham & Company — Analyst

Mani Foroohar — SVB Leerink — Analyst

Simon Baker — Redburn — Analyst

To read the full earnings call transcript, click here

Most Popular

Context Therapeutics: Another clinical-stage oncology research firm to go public soon

The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for

Biogen (BIIB) Stock: Does FDA nod for Aduhelm offer a buying opportunity?

The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant

IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know

Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated

Add Comment
Viewing Highlight